BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vyfhuis MAL, Rice S, Remick J, Mossahebi S, Badiyan S, Mohindra P, Simone CB 2nd. Reirradiation for locoregionally recurrent non-small cell lung cancer. J Thorac Dis 2018;10:S2522-36. [PMID: 30206496 DOI: 10.21037/jtd.2017.12.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Simone CB 2nd, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol 2020;30:253-61. [PMID: 32503791 DOI: 10.1016/j.semradonc.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Troost EGC, Wink KCJ, Roelofs E, Simone CB 2nd, Makocki S, Löck S, van Kollenburg P, Dechambre D, Minken AWH, van der Stoep J, Avery S, Jansen N, Solberg T, Bussink J, de Ruysscher D. Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO in silico study. Br J Radiol 2020;93:20190879. [PMID: 31804145 DOI: 10.1259/bjr.20190879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
3 Fischer-Valuck BW, Robinson CG, Simone CB 2nd, Gomez DR, Bradley JD. Challenges in Re-Irradiation in the Thorax: Managing Patients with Locally Recurrent Non-Small Cell Lung Cancer. Semin Radiat Oncol 2020;30:223-31. [PMID: 32503787 DOI: 10.1016/j.semradonc.2020.02.001] [Reference Citation Analysis]
4 Patel NV, Yu NY, Koroulakis A, Diwanji T, Sawant A, Sio TT, Mohindra P. Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Rev Anticancer Ther 2021;21:177-91. [PMID: 33118427 DOI: 10.1080/14737140.2021.1844567] [Reference Citation Analysis]
5 Hunter B, Crockett C, Faivre-Finn C, Hiley C, Salem A. Re-Irradiation of Recurrent Non-Small Cell Lung Cancer. Semin Radiat Oncol 2021;31:124-32. [PMID: 33610269 DOI: 10.1016/j.semradonc.2020.11.009] [Reference Citation Analysis]
6 Li W, Xiao H, Xu X, Zhang Y. The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries. Curr Oncol 2021;28:301-16. [PMID: 33435562 DOI: 10.3390/curroncol28010035] [Reference Citation Analysis]
7 Chinniah C, Aguarin L, Cheng P, Decesaris C, Cutillo A, Berman AT, Frick M, Doucette A, Cengel KA, Levin W, Hahn S, Dorsey JF, Simone CB 2nd, Kao GD. Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. Clin Lung Cancer 2019;20:384-390.e2. [PMID: 31221522 DOI: 10.1016/j.cllc.2019.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
8 Yang K, Suh Y, Shin H, Pyo H, Moon SH, Ahn YC, Oh D, Chung E, Jo K, Noh JM. Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer. Life 2022;12:292. [DOI: 10.3390/life12020292] [Reference Citation Analysis]
9 Paradis KC, Mayo C, Owen D, Spratt DE, Hearn J, Rosen B, Kashani R, Moran J, Tatro DS, Beeler W, Vineberg K, Smith DC, Matuszak MM. The Special Medical Physics Consult Process for Reirradiation Patients. Adv Radiat Oncol 2019;4:559-65. [PMID: 31681862 DOI: 10.1016/j.adro.2019.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
10 Zheng Q, Ding H, Wang L, Yan Y, Wan Y, Yi Y, Tao L, Zhu C. Circulating Exosomal miR-96 as a Novel Biomarker for Radioresistant Non-Small-Cell Lung Cancer. J Oncol 2021;2021:5893981. [PMID: 33727921 DOI: 10.1155/2021/5893981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Taugner J, Eze C, Käsmann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol 2020;15:148. [PMID: 32517716 DOI: 10.1186/s13014-020-01590-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Käsmann L, Janssen S, Baschnagel AM, Kruser TJ, Harada H, Aktan M, Rades D. Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancer-a multicenter study. Transl Lung Cancer Res 2020;9:232-8. [PMID: 32420062 DOI: 10.21037/tlcr.2020.01.19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Badiyan SN, Rutenberg MS, Hoppe BS, Mohindra P, Larson G, Hartsell WF, Tsai H, Zeng J, Rengan R, Glass E, Katz S, Vargas C, Feigenberg SJ, Simone CB 2nd. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Pract Radiat Oncol. 2019;9:280-288. [PMID: 30802618 DOI: 10.1016/j.prro.2019.02.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
14 Stirling RG, Chau C, Shareh A, Zalcberg J, Fischer BM. Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology 2021;16:784-97. [DOI: 10.1016/j.jtho.2021.01.1622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Rodríguez De Dios N, Navarro-Martin A, Cigarral C, Chicas-Sett R, García R, Garcia V, Gonzalez JA, Gonzalo S, Murcia-Mejía M, Robaina R, Sotoca A, Vallejo C, Valtueña G, Couñago F. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 2022; 13(4): 237-266 [DOI: 10.5306/wjco.v13.i4.237] [Reference Citation Analysis]